Azitra (AZTR) Accumulated Depreciation (2022 - 2023)
Azitra (AZTR) reported Accumulated Depreciation of $401987.0 for Q4 2023, up 40.29% on a YoY basis from $286549.0 in Q4 2022, and up 8.48% quarter-over-quarter from $370568.0 in Q3 2023.
Azitra (AZTR) Accumulated Depreciation (2022 - 2023) Analysis & Trends
Azitra has reported Accumulated Depreciation for 2 years, with the latest figure at $401987.0 in Q4 2023.
- For the quarter ending Q4 2023, Accumulated Depreciation rose 40.29% year-over-year to $401987.0; the trailing twelve-month figure through Dec 2023 stood at $401987.0 (up 40.29% YoY), and the FY2023 full-year result was $401987.0, up 40.29% from the prior year.
- Accumulated Depreciation for Q4 2023 stood at $401987.0, up from $370568.0 in the prior quarter.
- The five-year high for Accumulated Depreciation was $401987.0 in Q4 2023, with the low at $286549.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 401,987.00 |
| Sep 30, 2023 | 370,568.00 |
| Jun 30, 2023 | 349,531.00 |
| Dec 31, 2022 | 286,549.00 |